Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Antiviral Therapy|February 7, 2009
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancyNils von Hentig, Gabi Nisius, Tessa Lennemann, et al.
AIDS (London, England)|April 20, 2004
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavirChristoph Stephan, Nils von Hentig, Irene Kourbeti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2002
Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patientsUlrich A Walker, Markus Bickel, Severine I Lütke Volksbeck, et al.
AIDS (London, England)|May 16, 2007
Chronic renal failure among HIV-1-infected patientsAmanda Mocroft, Ole Kirk, Jose Gatell, et al.
Scandinavian Journal of Infectious Diseases|September 14, 2007
Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophyMarkus Bickel, Stephan Zangos, Thomas Lutz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individualsColette J Smith, Schlomo Staszewski, Caroline A Sabin, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2007
Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimenNils von Hentig, Axel Müller, Carsten Rottmann, et al.
British Journal of Clinical Pharmacology|October 26, 2006
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancyNils von Hentig, Amina Carlebach, Peter Gute, et al.
Antiviral Therapy|November 30, 2005
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapyAlessandro Cozzi-Lepri, Lidia Ruiz, Clive Loveday, et al.
AIDS (London, England)|November 14, 2008
Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis countryChristoph Stephan, Timo Wolf, Udo Goetsch, et al.
Pageof 7